Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020067228 - MARKER FOR ASSESSING SENSITIVITY TO COMBINATION ANTICANCER DRUG

Publication Number WO/2020/067228
Publication Date 02.04.2020
International Application No. PCT/JP2019/037733
International Filing Date 26.09.2019
IPC
A61K 31/282 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
282Platinum compounds
A61K 31/513 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
CPC
A61K 31/282
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
282Platinum compounds
A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • 学校法人慶應義塾 KEIO UNIVERSITY [JP]/[JP]
  • 株式会社ヤクルト本社 KABUSHIKI KAISHA YAKULT HONSHA [JP]/[JP]
Inventors
  • 杉本 伸二 SUGIMOTO, Shinji
  • 谷川原 祐介 TANIGAWARA, Yusuke
  • 松尾 光寿 MATSUO, Mitsuhisa
  • 高橋 寛行 TAKAHASHI, Hiroyuki
Agents
  • 特許業務法人アルガ特許事務所 THE PATENT CORPORATE BODY ARUGA PATENT OFFICE
Priority Data
2018-18514228.09.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) MARKER FOR ASSESSING SENSITIVITY TO COMBINATION ANTICANCER DRUG
(FR) MARQUEUR PERMETTANT D'ÉVALUER LA SENSIBILITÉ À UNE COMBINAISON DE MÉDICAMENTS ANTICANCÉREUX
(JA) 併用抗がん剤の感受性の判定マーカー
Abstract
(EN)
Provided is a marker for assessing sensitivity to an anticancer drug during the early stages after initiating treatment. This marker for assessing, during the early stages after initiating treatment, sensitivity to an anticancer drug containing oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof comprises one or more molecules selected from the group consisting of 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO and RIB5P.
(FR)
L'invention concerne un marqueur permettant d'évaluer la sensibilité à un médicament anticancéreux pendant les stades précoces après le début du traitement. Ce marqueur pour évaluer, pendant les stades précoces après le début du traitement, la sensibilité à un médicament anticancéreux contenant de l'oxaliplatine ou un sel de celui-ci, du fluoro-uracile ou un sel de celui-ci, et du lévofolinate ou un sel de celui-ci, comprend une ou plusieurs molécules choisies dans le groupe constitué par les composés suivants : 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO et RIB5P.
(JA)
抗がん剤治療開始後早期感受性判定マーカーの提供。2AMAD、2ABA、2CYPR、5OPRO、6AHXA、ADEN、ASP、BETNC、CARB、CSSG、DOPM、GGLCY、GSSG、HYPT、METSF、N6MDA、NOMTR、PHEP、PRO及びRIB5Pから選ばれる1以上の分子からなる、オキサリプラチン又はその塩とフルオロウラシル又はその塩とレボホリナート又はその塩を含む抗がん剤の治療開始後早期感受性判定マーカー。
Latest bibliographic data on file with the International Bureau